Management of the Metabolic Syndrome

Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats

“…Rats were left untreated from days 2-7 before the first antidiabetic drug administration (day 8) and the subsequent intraperitoneal glucose tolerance test (IGTT; day 9). As the present longitudinal study exposed the rats consecutively to 3 different antidiabetic drugs that could theoretically have residual carryover effects, a similar "washout" procedure was performed 1 week after each drug treatment (rats were left untreated during the week after each olanzapine/antidiabetic drug trial, days [10][11][12][13][14]. Any putative carryover effects would be detected as a change in IGTT results in the absence of drug challenge.…”

“…9 However, these changes may be more challenging in the psychiatric population, 10 therefore the mainstay of treatment remains the use of antidiabetic drugs. A number of different antidiabetic drugs are currently used to treat metabolic syndrome 11 and type II diabetes mellitus, but unlike antipsychotic drugs that all work primarily through a similar mechanism in regards to clinical efficacy (blockade of dopamine D 2 receptors 12 ), the antidiabetic drugs operate through diverse physiological pathways. For instance, the efficacy of metformin (a biguanide) is mediated in part by an AMP-dependent kinase (AMPK) signalling pathway, which does not directly stimulate insulin secretion.…”

Investigation of the Anti-Obesity Action of Licorice Flavonoid Oil in Diet-Induced Obese Rats

“…3) Hence new drugs and food ingredients that effectively suppress the accumulation of abdominal fat should be developed for pharmacotherapy or alimentotherapy for the syndrome.…”

The Characteristics of Living and Behavioral Factors in Chinese Patients with Metabolic Syndrome

“…1) It is associated with increased risk for the development of atherosclerosis and cardiovascular disease (CVD), which are serious health threats. 1,2) Therefore, on the basis of the diagnostic criteria of the World Health Organization (WHO) and National Cholesterol Education Program (NCEP), the International Diabetes Federation (IDF) proposed new criteria for diagnosing MS in 2005. The waistline is considered the central target and hypertension, dyslipidemia, and blood glucose abnormalities as judgment criteria.…”

“…These therapeutic measures are able to modify favorably the core components of MS and it is hoped that they will also improve the long-term cardiovascular prognosis in these patients. 2) This research aimed at investigating basic lifestyles or inappropriate habits that may speed the process of MS development and determine apparent risk factors so that countermeasures could be formu-lated to avoid it to some extent. We focused on root causes of the syndrome (atherogenic diet, sedentary lifestyle, and overweight/obesity) and highlight recent studies that have demonstrated the effectiveness of TLC in improving or preventing the components of MS through a practical approach with a focus that embraces not only patients but also physicians and healthcare professionals as well as the larger healthcare system.…”